M.V. Lebedeva

Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Background. Chronic obstructive pulmonary disease (COPD) is a widespread acquired disease, accompanied by irreversible bronchial obstruction and significantly impaired quality of life. Tobacco addiction, as well as comorbid conditions, complicating the health of patients in the second half of life, often make it difficult to individually select the drug therapy for COPD. Undoubtedly, optimal bronchodilation is a key part of the pharmacotherapy of this disease, while the expanded range of drugs allows individual approach to the choice of therapy for each patient. Description of the clinical case. The article presents several clinical examples of the course of COPD, in which the condition was stabilized with glycopyrronium bromide, an anticholinergic drug with 24-hour duration of action, as a background therapy. Conclusion. The unique pharmacological as well as clinical properties of the molecule described in this article allow this bronchodilator to be used in various clinical situations of the COPD course – against smoking cessation, as a monotherapy, and as an addition to the available background therapy in the presence of concomitant pathology. Stabilization of the clinical condition of patients against the background of improvement of spirometric parameters proves the high clinical effectiveness of glycopyrronium in COPD therapy.
Keywords: COPD, long-acting anticholinergic drug, glycopyrronium bromide

About the Autors

Corresponding author: M.V. Lebedeva – PhD, Associate Professor at the Department of Internal Diseases, Occupational Diseases and Pulmonology of the Medical-Preventive Faculty, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; e-mail:, ORCID:, Scopus Author ID: /authid/detail.uri?authorId=7101812367

Бионика Медиа